UA73986C2 - АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ - Google Patents
АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ Download PDFInfo
- Publication number
- UA73986C2 UA73986C2 UA2002118859A UA2002118859A UA73986C2 UA 73986 C2 UA73986 C2 UA 73986C2 UA 2002118859 A UA2002118859 A UA 2002118859A UA 2002118859 A UA2002118859 A UA 2002118859A UA 73986 C2 UA73986 C2 UA 73986C2
- Authority
- UA
- Ukraine
- Prior art keywords
- formoterol
- nea
- cylinders
- acid
- solution composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 15
- 239000000443 aerosol Substances 0.000 title abstract description 12
- 239000000048 adrenergic agonist Substances 0.000 title description 2
- 238000000034 method Methods 0.000 title description 2
- 230000002035 prolonged effect Effects 0.000 title 1
- 239000002253 acid Substances 0.000 abstract description 17
- 239000003380 propellant Substances 0.000 abstract description 9
- 229910052782 aluminium Inorganic materials 0.000 abstract description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 8
- 239000006184 cosolvent Substances 0.000 abstract description 8
- 150000005828 hydrofluoroalkanes Chemical class 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 229910001220 stainless steel Inorganic materials 0.000 abstract description 2
- 239000010935 stainless steel Substances 0.000 abstract description 2
- 239000011149 active material Substances 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 31
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 23
- 229960002848 formoterol Drugs 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 9
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 9
- 229960000193 formoterol fumarate Drugs 0.000 description 9
- 229960002052 salbutamol Drugs 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000003513 alkali Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- -1 hydrochloric Chemical class 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BNPSSFBOAGDEEL-NMFAMCKASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-NMFAMCKASA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- YACLQRRMGMJLJV-UHFFFAOYSA-N chloroprene Chemical compound ClC(=C)C=C YACLQRRMGMJLJV-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000005007 epoxy-phenolic resin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- SYCWERNQGSKYAG-QVRIGTRMSA-N hydron;8-hydroxy-5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1h-quinolin-2-one;chloride Chemical compound Cl.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 SYCWERNQGSKYAG-QVRIGTRMSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2000/004635 WO2001089480A1 (en) | 2000-05-22 | 2000-05-22 | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73986C2 true UA73986C2 (uk) | 2005-10-17 |
Family
ID=8163952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002118859A UA73986C2 (uk) | 2000-05-22 | 2000-05-22 | АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ |
Country Status (40)
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| DZ2947A1 (fr) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| AU1534501A (en) * | 1999-11-23 | 2001-06-04 | Glaxo Group Limited | Pharmaceutical formulations of salmeterol |
| IT1317720B1 (it) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| JP5392880B2 (ja) * | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| HUP0302005A3 (en) * | 2000-05-23 | 2006-07-28 | Glaxo Group Ltd | Aerosol container for formulations of salmeterol xinafoate |
| FI20002177A0 (fi) * | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | Uusi yhdistelmä astman hoitoon |
| EP1241113A1 (en) | 2001-03-12 | 2002-09-18 | CHIESI FARMACEUTICI S.p.A. | Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein |
| EP1372608B1 (de) * | 2001-03-30 | 2007-10-10 | Jagotec Ag | Medizinische aerosolformulierungen |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| PT1273292E (pt) | 2001-07-02 | 2004-10-29 | Chiesi Farma Spa | Formulacao optimizada de tobramicina para aerossolizacao |
| US7306925B2 (en) | 2001-11-09 | 2007-12-11 | Vanderbilt University | Phage antibodies to radiation-inducible neoantigens |
| US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
| EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
| SI3536344T1 (sl) * | 2002-03-01 | 2020-06-30 | Chiesi Farmaceutici S.P.A. | Superfina formulacija formoterola |
| EP1415647A1 (en) * | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
| US20040166065A1 (en) | 2002-08-14 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosol formulation for inhalation comprising an anticholinergic |
| PL375511A1 (en) * | 2002-08-14 | 2005-11-28 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Aerosol formulation for inhalation containing an anticholinergic agent |
| DE10237739A1 (de) * | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| US7244742B2 (en) * | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| US20050003024A1 (en) * | 2003-03-04 | 2005-01-06 | The Procter & Gamble Company | Regulation of mammalian hair growth |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| NZ545442A (en) * | 2003-07-29 | 2010-05-28 | Boehringer Ingelheim Int | Medicaments for inhalation comprising betamimetics and an aclidinium salt known as 3-(2-hydroxy-2,2-dithiophen-2-yl-acetoxy)-1-(3-phenoxypropyl)-l-azoniabicyclo[2.2.2]octane |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| CA2534120C (en) * | 2003-07-31 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising anticholinergics and a betamimetic |
| EP1654001A2 (en) * | 2003-08-05 | 2006-05-10 | Boehringer Ingelheim International GmbH | Medicaments for inhalation comprising steroids and a betamimetic |
| BRPI0414428A (pt) * | 2003-09-15 | 2006-11-14 | Vectura Ltd | composições farmacêuticas |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| AR041873A1 (es) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
| KR20070000476A (ko) * | 2004-02-27 | 2007-01-02 | 키에시 파르마슈티시 엣스. 피. 에이. | 압축화 계량된 도스흡입용 안정된 약제용액 제제 |
| EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| UA88894C2 (ru) * | 2004-02-27 | 2009-12-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Стабильные фармацевтические композиции в виде растворов для ингаляторов с дозатором, которые находятся под давлением |
| KR20070010159A (ko) * | 2004-05-13 | 2007-01-22 | 키에시 파르마슈티시 엣스. 피. 에이. | 화학안정성이 향상된 약제 에어로졸 제제 생성물 |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
| CN101119706B (zh) * | 2005-02-25 | 2013-04-17 | 奇斯药制品公司 | 用于加压计量吸入器的包含螯合剂的药物气雾制剂 |
| JP2008534611A (ja) * | 2005-03-30 | 2008-08-28 | シェーリング コーポレイション | 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法 |
| DE102005055960A1 (de) * | 2005-11-24 | 2007-07-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum |
| GB0525680D0 (en) | 2005-12-16 | 2006-01-25 | Peplin Ltd | Therapeutic compositions |
| US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
| GB0613761D0 (en) * | 2006-07-11 | 2006-08-23 | Norton Healthcare Ltd | A pharmaceutical formulation and method for the preparation thereof |
| EP1982709A1 (en) | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| US8227027B2 (en) * | 2007-12-07 | 2012-07-24 | Presspart Gmbh & Co. Kg | Method for applying a polymer coating to an internal surface of a container |
| EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| US20090208424A1 (en) * | 2008-02-19 | 2009-08-20 | Todd Maibach | Compositions and methods for delivery of solution to the skin |
| US20100055045A1 (en) * | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2257172A4 (en) * | 2008-02-26 | 2013-07-03 | Elevation Pharmaceuticals Inc | METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| US20110250242A1 (en) * | 2008-10-23 | 2011-10-13 | Sunovion Pharmaceuticals Inc. | Arformoterol and tiotropium compositions and methods for use |
| EP2201934A1 (en) * | 2008-12-23 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Tiotropium aerosol formulation products with improved chemical stability |
| JP5670421B2 (ja) | 2009-03-31 | 2015-02-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | コンポーネント表面のコーティング方法 |
| US9265910B2 (en) | 2009-05-18 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and nebulizer |
| PL2727582T3 (pl) * | 2009-10-02 | 2016-06-30 | Chiesi Farm Spa | Farmaceutyczne formulacje aerozolowe formoterolu i dipropionianu beklometazonu |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
| GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| JP5715640B2 (ja) | 2009-11-25 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| EP2504051B1 (en) | 2009-11-25 | 2019-09-04 | Boehringer Ingelheim International GmbH | Nebulizer |
| EP2512438B1 (en) | 2009-12-16 | 2017-01-25 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| ES2468835T3 (es) | 2009-12-23 | 2014-06-17 | Chiesi Farmaceutici S.P.A. | Terapia combinada para EPOC |
| SG181868A1 (en) | 2009-12-23 | 2012-07-30 | Chiesi Farma Spa | Combination therapy for copd |
| EP2515854B1 (en) | 2009-12-23 | 2014-03-19 | Chiesi Farmaceutici S.p.A. | Aerosol formualtion for COPD |
| US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2012010854A1 (en) | 2010-07-23 | 2012-01-26 | Cipla Limited | Inhalation formulations comprising carmoterol in combination with a corticosteroid |
| WO2012130757A1 (de) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medizinisches gerät mit behälter |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2013019730A1 (en) | 2011-07-29 | 2013-02-07 | The Washington University | Antibodies to tip-1 and grp78 |
| GB201200504D0 (en) * | 2011-12-19 | 2012-02-22 | Teva Branded Pharmaceutical Prod R & D Inc | An inhaler |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
| JP6643231B2 (ja) | 2013-08-09 | 2020-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| EP2835146B1 (en) | 2013-08-09 | 2020-09-30 | Boehringer Ingelheim International GmbH | Nebulizer |
| PL3089735T3 (pl) * | 2013-12-30 | 2018-12-31 | Chiesi Farmaceutici S.P.A. | Trwała ciśnieniowa kompozycja roztworu aerozolowego kombinacji bromku glikopironium i formoterolu |
| GEP20186870B (en) * | 2013-12-30 | 2018-06-25 | Chiesi Farma Spa | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
| DK3139984T3 (da) | 2014-05-07 | 2021-07-19 | Boehringer Ingelheim Int | Forstøver |
| CN106255554B (zh) | 2014-05-07 | 2021-05-04 | 勃林格殷格翰国际有限公司 | 容器、喷雾器及用途 |
| PT3139982T (pt) | 2014-05-07 | 2022-04-05 | Boehringer Ingelheim Int | Nebulizador |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| EP3172222A4 (en) | 2014-07-24 | 2018-03-21 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
| CN104225739A (zh) * | 2014-09-30 | 2014-12-24 | 四川普锐特医药科技有限责任公司 | 一种医用定量吸入气雾剂 |
| CN108289843B (zh) | 2015-12-04 | 2021-08-17 | 墨西哥氟石股份公司 | 药物组合物 |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| EP3634459A4 (en) | 2017-02-10 | 2021-01-06 | Washington University | ANTIBODIES DIRECTED AGAINST TIP1 AND THEIR PROCEDURES FOR USE |
| JOP20200314A1 (ar) | 2018-06-04 | 2020-12-06 | Lupin Inc | تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة |
| WO2020152548A1 (en) * | 2019-01-24 | 2020-07-30 | Glenmark Pharmaceuticals Limited | Stable aerosol inhalation compositions of formoterol |
| CN112137957B (zh) | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| NZ786610A (en) | 2019-12-02 | 2025-06-27 | Chiesi Farm Spa | Stainless steel can for pressurised metered dose inhalers |
| GB2593283B (en) | 2020-01-28 | 2023-09-13 | Chiesi Farm Spa | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| GB202001537D0 (en) * | 2020-02-05 | 2020-03-18 | Consort Medical Plc | Pressurised dispensing container |
| PE20230236A1 (es) | 2020-02-20 | 2023-02-07 | Chiesi Farm Spa | Inhaladores dosificadores presurizados que comprenden una formulacion farmaceutica amortiguada |
| US11826382B2 (en) | 2020-05-01 | 2023-11-28 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
| US12042514B2 (en) | 2020-05-01 | 2024-07-23 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
| US11642372B2 (en) * | 2020-05-01 | 2023-05-09 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
| BR112023001689A2 (pt) | 2020-07-31 | 2023-05-02 | Chemo Res S L | Terapia de combinação para administração por inalação |
| CA3193038A1 (en) * | 2020-10-09 | 2022-04-14 | Enrico Zambelli | A pharmaceutical formulation for pressurised metered dose inhaler |
| GB2614901A (en) | 2022-01-21 | 2023-07-26 | Nanopharm Ltd | Inhalable formulations |
| EP4504338A1 (en) | 2022-04-06 | 2025-02-12 | RAPT Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
| CN119630425A (zh) | 2022-05-27 | 2025-03-14 | 奇斯药制品公司 | 用于加压定量吸入器的药物制剂 |
| CN119255820A (zh) | 2022-05-27 | 2025-01-03 | 奇斯药制品公司 | 用于加压定量吸入器的药物制剂 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3622053A (en) | 1969-12-10 | 1971-11-23 | Schering Corp | Aerosol inhaler with flip-up nozzle |
| MX3864E (es) | 1975-05-27 | 1981-08-26 | Syntex Corp | Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona |
| US4185100A (en) | 1976-05-13 | 1980-01-22 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
| US4499108A (en) * | 1983-06-08 | 1985-02-12 | Schering Corporation | Stable pleasant-tasting albuterol sulfate pharmaceutical formulations |
| GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| IT1196142B (it) | 1984-06-11 | 1988-11-10 | Sicor Spa | Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti |
| US5192528A (en) | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| IE67185B1 (en) * | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| KR930703251A (ko) | 1990-12-19 | 1993-11-29 | 스튜어트 알. 슈터 | 에어로졸 제제 |
| US6006745A (en) | 1990-12-21 | 1999-12-28 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| ATE171630T1 (de) | 1991-05-21 | 1998-10-15 | Abbott Lab | Aerosolinhalationsvorrichtung |
| US5435297A (en) | 1991-08-29 | 1995-07-25 | Christoph Klein | Medical device for inhaling metered aerosols |
| IL103238A (en) | 1991-09-25 | 1995-07-31 | Fisons Plc | Pressurised aerosol compositions |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| DK1086688T3 (da) * | 1991-12-18 | 2004-08-16 | Minnesota Mining & Mfg | Aerosolformuleringer til suspensioner |
| DE4230876A1 (de) | 1992-03-17 | 1993-09-23 | Asta Medica Ag | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten |
| DE69324161T2 (de) | 1992-12-09 | 1999-10-28 | Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield | Stabilisierte medizinische aerosollösungen |
| SE9203743D0 (sv) * | 1992-12-11 | 1992-12-11 | Astra Ab | Efficient use |
| AU4066693A (en) | 1992-12-23 | 1994-07-19 | Bernhard Hugemann | Compacted drug body for use in the mechanical generation of inhalable active-substance particles |
| KR100321650B1 (ko) * | 1993-03-17 | 2002-07-27 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | 디올/디산계분산보조제를함유하는분무제제 |
| AU679511B2 (en) * | 1993-03-17 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
| US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
| DK0735884T3 (da) | 1993-12-20 | 2000-10-09 | Minnesota Mining & Mfg | Flunisolid-aerosolformuleringer |
| GB9425160D0 (en) * | 1994-12-10 | 1995-02-08 | Glaxo Group Ltd | Medicaments |
| EP0806940B1 (en) * | 1994-12-22 | 2003-04-09 | AstraZeneca AB | Aerosol drug formulations |
| GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
| DE4446891A1 (de) | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
| US5653961A (en) | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
| EP1870122A3 (en) | 1995-04-14 | 2008-03-12 | SmithKline Beecham Corporation | Metered dose inhaler |
| EP0820322B1 (en) | 1995-04-14 | 2002-07-10 | SmithKline Beecham Corporation | Metered dose inhaler for fluticasone propionate |
| ATE258813T1 (de) | 1995-04-14 | 2004-02-15 | Smithkline Beecham Corp | Vorrichtung zur dosierten inhalierung von beclomethason-diproprionat |
| CA2217954C (en) | 1995-04-14 | 2005-02-15 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
| US6135628A (en) * | 1995-10-13 | 2000-10-24 | Boehringer Ingelheim Pharmceuticals, Inc. | Method and apparatus for homogenizing aerosol formulations |
| GB9612297D0 (en) * | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| JP2000514085A (ja) | 1996-07-08 | 2000-10-24 | ローヌ―プーラン・ロウラー・リミテッド | 医薬シクロスポリンａエーロゾル溶液処方物 |
| WO1998003533A1 (en) | 1996-07-24 | 1998-01-29 | Oligos Etc. And Oligos Therapeutics, Inc. | Antisense oligonucleotides as antibacterial agents |
| GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| GB9620187D0 (en) | 1996-09-27 | 1996-11-13 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| CA2273835A1 (en) * | 1996-12-04 | 1998-06-11 | Bioglan Ireland (R & D) Limited | Pharmaceutical compositions and devices for their administration |
| US6413496B1 (en) | 1996-12-04 | 2002-07-02 | Biogland Ireland (R&D) Limited | Pharmaceutical compositions and devices for their administration |
| AU718967B2 (en) | 1997-02-05 | 2000-05-04 | Jagotec Ag | Medical aerosol formulations |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| US5891419A (en) | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe flunisolide aerosol formulations for oral inhalation |
| US6000537A (en) * | 1997-06-10 | 1999-12-14 | U.S. Philips Corporation | Housing with readable side walls for a disc-shaped information carrier |
| GB2326334A (en) * | 1997-06-13 | 1998-12-23 | Chiesi Farma Spa | Pharmaceutical aerosol compositions |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| US6324827B1 (en) * | 1997-07-01 | 2001-12-04 | Bp Corporation North America Inc. | Method of generating power in a dry low NOx combustion system |
| BR7702049U (pt) | 1997-09-05 | 1999-09-14 | Chiesi Farma Spa | Bico pulverizador para utilização em inalador oral para medicamentos aerossóis |
| US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
| AU2081999A (en) * | 1998-01-13 | 1999-08-02 | Astrazeneca Uk Limited | Pharmaceutical compostition comprising a compound having dopamine (D2) receptor agonist activity and a compound (B) having Beta2 adrenoreceptor agonist activity |
| US6045784A (en) | 1998-05-07 | 2000-04-04 | The Procter & Gamble Company | Aerosol package compositions containing fluorinated hydrocarbon propellants |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| CZ300910B6 (cs) * | 1998-06-18 | 2009-09-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Farmaceutický prostredek |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| WO2000006121A1 (de) * | 1998-07-24 | 2000-02-10 | Jago Research Ag | Medizinische aerosolformulierungen |
| NZ509489A (en) * | 1998-08-04 | 2002-10-25 | Jago Res A | Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil |
| US6136294C1 (en) * | 1998-09-22 | 2002-09-24 | Aeropharm Technology Inc | Amino acid stabilized medical aerosol formulation |
| DE19847969A1 (de) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähig flüssige Formulierung mit Formoterol |
| HK1041448B (zh) * | 1998-10-17 | 2005-05-13 | 贝林格尔英格海姆法玛两合公司 | 可儲存的含福莫特羅的活性物質濃縮液 |
| DE59904488D1 (de) | 1998-11-13 | 2003-04-10 | Jago Res Ag Muttenz | Trockenpulver zur inhalation |
| DZ2947A1 (fr) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| US6290930B1 (en) | 1998-12-18 | 2001-09-18 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| ES2286881T3 (es) | 1999-03-05 | 2007-12-01 | Chiesi Farmaceutici S.P.A. | Composiciones farmaceuticas en polvo mejoradas para inhalacion. |
| US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
| JP2003518484A (ja) | 1999-12-24 | 2003-06-10 | グラクソ グループ リミテッド | サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤 |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| IT1318514B1 (it) | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
| JP5392880B2 (ja) * | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
| SI3536344T1 (sl) * | 2002-03-01 | 2020-06-30 | Chiesi Farmaceutici S.P.A. | Superfina formulacija formoterola |
| EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
-
2000
- 2000-05-22 JP JP2001585725A patent/JP5392880B2/ja not_active Expired - Lifetime
- 2000-05-22 CN CNB008195641A patent/CN1213732C/zh not_active Expired - Lifetime
- 2000-05-22 HR HRP20021025AA patent/HRP20021025B1/hr not_active IP Right Cessation
- 2000-05-22 CA CA002411047A patent/CA2411047C/en not_active Expired - Lifetime
- 2000-05-22 EA EA200201058A patent/EA005179B1/ru not_active IP Right Cessation
- 2000-05-22 MX MXPA02011414A patent/MXPA02011414A/es active IP Right Grant
- 2000-05-22 CZ CZ20023835A patent/CZ303833B6/cs not_active IP Right Cessation
- 2000-05-22 IL IL15295500A patent/IL152955A0/xx unknown
- 2000-05-22 DZ DZ003358A patent/DZ3358A1/fr active
- 2000-05-22 ME MEP-2008-321A patent/ME00220B/me unknown
- 2000-05-22 WO PCT/EP2000/004635 patent/WO2001089480A1/en active Application Filing
- 2000-05-22 EE EEP200200649A patent/EE05167B1/xx unknown
- 2000-05-22 AU AU5070100A patent/AU5070100A/xx active Pending
- 2000-05-22 UA UA2002118859A patent/UA73986C2/uk unknown
- 2000-05-22 BR BR0015884-4A patent/BR0015884A/pt not_active IP Right Cessation
- 2000-05-22 HU HU0302007A patent/HU230804B1/hu active Protection Beyond IP Right Term
- 2000-05-22 AU AU2000250701A patent/AU2000250701B2/en not_active Expired
- 2000-05-22 SK SK1652-2002A patent/SK286694B6/sk not_active IP Right Cessation
-
2001
- 2001-05-17 JO JO200172A patent/JO2310B1/en active
- 2001-05-17 PE PE2001000439A patent/PE20011323A1/es not_active Application Discontinuation
- 2001-05-18 PT PT01112230T patent/PT1157689E/pt unknown
- 2001-05-18 ES ES10166800T patent/ES2380790T3/es not_active Expired - Lifetime
- 2001-05-18 ES ES01112230T patent/ES2320194T3/es not_active Expired - Lifetime
- 2001-05-18 EP EP07004772A patent/EP1787639B1/en not_active Expired - Lifetime
- 2001-05-18 SI SI200130992T patent/SI1787639T1/sl unknown
- 2001-05-18 SI SI200130907T patent/SI1157689T1/sl unknown
- 2001-05-18 PT PT10166800T patent/PT2223682E/pt unknown
- 2001-05-18 DK DK07004772.5T patent/DK1787639T3/da active
- 2001-05-18 DE DE60136864T patent/DE60136864D1/de not_active Expired - Lifetime
- 2001-05-18 MY MYPI20060219A patent/MY143733A/en unknown
- 2001-05-18 PT PT04011423T patent/PT1466594E/pt unknown
- 2001-05-18 EP EP04011423A patent/EP1466594B1/en not_active Expired - Lifetime
- 2001-05-18 ES ES04011423T patent/ES2318217T3/es not_active Expired - Lifetime
- 2001-05-18 SI SI200130902T patent/SI1466594T1/sl unknown
- 2001-05-18 DE DE60144304T patent/DE60144304D1/de not_active Expired - Lifetime
- 2001-05-18 AT AT01112230T patent/ATE419832T1/de active
- 2001-05-18 MY MYPI20012370 patent/MY127145A/en unknown
- 2001-05-18 AT AT07004772T patent/ATE502624T1/de active
- 2001-05-18 PT PT07004772T patent/PT1787639E/pt unknown
- 2001-05-18 EP EP10166800A patent/EP2223682B1/en not_active Expired - Lifetime
- 2001-05-18 EP EP01112230A patent/EP1157689B1/en not_active Revoked
- 2001-05-18 AT AT04011423T patent/ATE415945T1/de active
- 2001-05-18 DK DK01112230T patent/DK1157689T3/da active
- 2001-05-18 DE DE122009000035C patent/DE122009000035I1/de active Pending
- 2001-05-18 SI SI200131010T patent/SI2223682T1/sl unknown
- 2001-05-18 AT AT10166800T patent/ATE541563T1/de active
- 2001-05-18 ES ES07004772T patent/ES2359991T3/es not_active Expired - Lifetime
- 2001-05-18 DK DK04011423T patent/DK1466594T3/da active
- 2001-05-18 DE DE60137282T patent/DE60137282D1/de not_active Expired - Lifetime
- 2001-05-18 DK DK10166800.2T patent/DK2223682T3/da active
- 2001-05-21 US US09/860,689 patent/US6716414B2/en not_active Expired - Lifetime
- 2001-05-21 AR ARP010102397A patent/AR029523A1/es not_active Application Discontinuation
- 2001-05-21 SA SA01220126A patent/SA01220126B1/ar unknown
- 2001-05-22 TN TNTNSN01074A patent/TNSN01074A1/fr unknown
- 2001-05-22 TW TW090112202A patent/TWI284047B/zh not_active IP Right Cessation
-
2002
- 2002-11-08 BG BG107256A patent/BG65883B1/bg unknown
- 2002-11-20 NO NO20025568A patent/NO342935B1/no not_active IP Right Cessation
- 2002-11-20 IL IL152955A patent/IL152955A/en not_active IP Right Cessation
-
2003
- 2003-08-14 US US10/640,005 patent/US7018618B2/en not_active Expired - Lifetime
-
2005
- 2005-05-22 ME MEP-321/08A patent/MEP32108A/xx unknown
- 2005-11-30 US US11/289,479 patent/US20060083693A1/en not_active Abandoned
-
2009
- 2009-02-27 CY CY20091100233T patent/CY1108833T1/el unknown
- 2009-04-03 CY CY20091100391T patent/CY1108968T1/el unknown
- 2009-07-03 NL NL300393C patent/NL300393I2/nl unknown
- 2009-07-03 CY CY2009009C patent/CY2009009I1/el unknown
-
2011
- 2011-06-20 CY CY20111100584T patent/CY1111570T1/el unknown
- 2011-09-20 DE DE201112100049 patent/DE122011100049I1/de active Pending
- 2011-09-20 LT LTPA2011011C patent/LTC1787639I2/lt unknown
- 2011-09-20 BE BE2011C032C patent/BE2011C032I2/nl unknown
- 2011-09-21 LU LU91875C patent/LU91875I2/fr unknown
- 2011-09-22 CY CY2011014C patent/CY2011014I2/el unknown
- 2011-09-23 FR FR11C0041C patent/FR11C0041I2/fr active Active
-
2012
- 2012-04-18 CY CY20121100369T patent/CY1113028T1/el unknown
-
2018
- 2018-07-13 HU HUS1800032C patent/HUS1800032I1/hu unknown
-
2019
- 2019-01-16 NO NO2019003C patent/NO2019003I1/no unknown
- 2019-07-11 NO NO2019030C patent/NO2019030I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA73986C2 (uk) | АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ | |
| DK3089735T3 (en) | STABLE PRESSURE AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION | |
| BG62119B1 (bg) | Лекарствено средство | |
| AU2012358475B2 (en) | An inhalable medicament comprising tiotropium | |
| US20070256685A1 (en) | Aerosol Formulations Comprising Formoterol Fumarate Dihydrate | |
| EP1670443B1 (en) | Aerosol formulation comprising formoterol in suspension | |
| Murata et al. | Effect of the moisture content in aerosol on the spray performance of Stmerin® D hydrofluoroalkane preparations (2) | |
| US20170020852A1 (en) | Inhalable Medicament Comprising Tiotropium | |
| JP5409594B2 (ja) | 加圧式定量吸入器のための安定な製薬学的溶液製剤 | |
| CA3152578A1 (en) | Stainles steel can for pressurised metered dose inhalers |